Regulatory uniQure sets course to US filing for Huntington gene therapy PharmaphorumShares in uniQure have rocketed this morning, as it emerges that the FDA will not require it to run a new trial of Huntington's gene therapy AMT-130.NeuroscienceRead full story pharminent June 17, 2026 (Last updated: June 18, 2026) Pharmaphorum Shares in uniQure have rocketed this morning, as it emerges that the FDA will not require it to run a new trial of Huntington’s gene therapy AMT-130. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Jazz orchestrates a $4bn cancer alliance with AbCelleraNext: UniQure to file gene therapy for approval, reflecting major shifts at FDA Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
